Stroke (Cardiovascular) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Stroke – Drugs In Development, 2021, provides an overview of the Stroke (Cardiovascular) pipeline landscape.Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Stroke – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 43, 29, 3, 6, 145, 23 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 35 and 6 molecules, respectively.

Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).

– The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

4B Technologies (Suzhou) Co Ltd

AbbVie Inc

Acticor Biotech SAS

advanceCor GmbH

Advanced BioMatrix Inc

AegisCN LLC

Aegle Therapeutics Corp

Affibody AB

Akome Biotech Ltd

Algernon Pharmaceuticals Inc

Allife Medical Science and Technology Co Ltd

Anavex Life Sciences Corp

Angion Biomedica Corp

Ankasa Regenerative Therapeutics Inc

Annovis Bio Inc

Anthos Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Stroke - Overview

Stroke - Therapeutics Development

Stroke - Therapeutics Assessment

Stroke - Companies Involved in Therapeutics Development

Stroke - Drug Profiles

Stroke - Dormant Projects

Stroke - Discontinued Products

Stroke - Product Development Milestonesh

Appendix

List of Tables

List of Tables

Number of Products under Development for Stroke, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Stroke – Pipeline by 4B Technologies (Suzhou) Co Ltd, 2021

Stroke – Pipeline by AbbVie Inc, 2021

Stroke – Pipeline by Acticor Biotech SAS, 2021

Stroke – Pipeline by advanceCor GmbH, 2021

Stroke – Pipeline by Advanced BioMatrix Inc, 2021

Stroke – Pipeline by AegisCN LLC, 2021

Stroke – Pipeline by Aegle Therapeutics Corp, 2021

Stroke – Pipeline by Affibody AB, 2021

Stroke – Pipeline by Akome Biotech Ltd, 2021

Stroke – Pipeline by Algernon Pharmaceuticals Inc, 2021

Stroke – Pipeline by Allife Medical Science and Technology Co Ltd, 2021

Stroke – Pipeline by Anavex Life Sciences Corp, 2021

Stroke – Pipeline by Angion Biomedica Corp, 2021

Stroke – Pipeline by Ankasa Regenerative Therapeutics Inc, 2021

Stroke – Pipeline by Annovis Bio Inc, 2021

Stroke – Pipeline by Anthos Therapeutics Inc, 2021

Stroke – Pipeline by AntiRadical Therapeutics LLC, 2021

Stroke – Pipeline by Antoxis Ltd, 2021

Stroke – Pipeline by Apellis Pharmaceuticals Inc, 2021

Stroke – Pipeline by Aposcience AG, 2021

Stroke – Pipeline by APT Therapeutics Inc, 2021

Stroke – Pipeline by Zhejiang Ausun Pharmaceutical Co Ltd, 2021

Stroke – Pipeline by Zhittya Genesis Medicine Inc, 2021

Stroke – Pipeline by Zocere Inc, 2021

Stroke – Pipeline by ZyVersa Therapeutics Inc, 2021

Stroke – Pipeline by ZZ Biotech LLC, 2021

Stroke – Dormant Projects, 2021

Stroke – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Stroke, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports